Piramal Pharma Digwal facility successfully concludes USFDA inspection
Mumbai: Piramal Pharma Limited has recently announced that the US Food and Drug Administration (USFDA) has successfully completed the Good Manufacturing Practices (GMP) inspection with Zero Form - 483 observations at the company's Digwal facility.
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
The facility was inspected from 27th March, 2023 to 31st March, 2023.
"This is to inform you that the US FDA conducted a Good Manufacturing Practices (GMP) Inspection of Piramal Pharma Limited's Digwal facility from 27th March, 2023 to 31st March, 2023," the company stated in a BSE filing.
"The Company remains committed to maintain the highest standards of compliance," Piaramal further added.
Read also: USFDA inspection: Piramal Pharma gets Form 483 with 6 observations for Lexington facility
Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products.
PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC’s complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. In addition, PPL has a joint venture with Allergan. In October 2020, the company received a growth equity investment from the Carlyle Group.
Read also: Piramal Pharma Consumer Products Division unveils D2C platform Wellify.in
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd